135 related articles for article (PubMed ID: 9619361)
21. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
22. The prostate cancer conundrum.
Albertsen PC
J Natl Cancer Inst; 2003 Jul; 95(13):930-1. PubMed ID: 12837821
[No Abstract] [Full Text] [Related]
23. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
Ng CK; Moussa M; Downey DB; Chin JL
J Urol; 2007 Oct; 178(4 Pt 1):1253-7; discussion 1257. PubMed ID: 17698104
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
25. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
[TBL] [Abstract][Full Text] [Related]
26. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
27. [Salvage radiotherapy in rising PSA after radical prostatectomy].
Carrie C; Pommier P
Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
[TBL] [Abstract][Full Text] [Related]
28. Treatment options in hormone resistant prostate cancer.
De Mulder PH; Schalken JA; Sternberg CN
Ann Oncol; 2002; 13 Suppl 4():95-102. PubMed ID: 12401673
[No Abstract] [Full Text] [Related]
29. Current world literature.
Curr Opin Urol; 2013 Jul; 23(4):377-88. PubMed ID: 23735869
[No Abstract] [Full Text] [Related]
30. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
31. Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer.
Chen BT; Wood DP
Urology; 2003 Dec; 62 Suppl 1():69-78. PubMed ID: 14747044
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer.
Cannon GM; Walsh PC; Partin AW; Pound CR
Urology; 2003 Dec; 62 Suppl 1():2-8. PubMed ID: 14747037
[TBL] [Abstract][Full Text] [Related]
34. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
35. Proceedings of the 1st International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Boston, Massachusetts, March 29-30, 1996.
Urology; 1997 Mar; 49(3A Suppl):1-118; quiz 121-3. PubMed ID: 9123726
[No Abstract] [Full Text] [Related]
36. Re: Adverse Pathology and Undetectable Ultrasensitive Prostate-Specific Antigen after Radical Prostatectomy: Is Adjuvant Radiation Warranted?
Taneja SS
J Urol; 2015 Dec; 194(6):1631-2. PubMed ID: 26582665
[No Abstract] [Full Text] [Related]
37. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.
Prapotnich D; Fizazi K; Escudier B; Mombet A; Cathala N; Vallancien G
Eur Urol; 2003 Mar; 43(3):233-39; discussion 239-40. PubMed ID: 12600425
[TBL] [Abstract][Full Text] [Related]
38. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
39. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
Choueiri TK; Chen MH; D'Amico AV; Sun L; Nguyen PL; Hayes JH; Robertson CN; Walther PJ; Polascik TJ; Albala DM; Moul JW
Cancer; 2010 Apr; 116(8):1887-92. PubMed ID: 20162710
[TBL] [Abstract][Full Text] [Related]
40. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
